Concepts (250)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Genetics, Medical | 5 | 2022 | 17 | 1.490 |
Why?
|
| Neural Tube Defects | 6 | 2021 | 27 | 1.160 |
Why?
|
| Genetic Testing | 7 | 2021 | 159 | 0.810 |
Why?
|
| Down Syndrome | 4 | 2022 | 120 | 0.750 |
Why?
|
| Folic Acid | 4 | 2013 | 123 | 0.690 |
Why?
|
| Prenatal Diagnosis | 9 | 2022 | 73 | 0.600 |
Why?
|
| Cell-Free Nucleic Acids | 3 | 2020 | 11 | 0.510 |
Why?
|
| Genomics | 6 | 2022 | 168 | 0.490 |
Why?
|
| Pregnancy | 16 | 2022 | 2334 | 0.400 |
Why?
|
| Papio | 2 | 2003 | 27 | 0.370 |
Why?
|
| Aneuploidy | 5 | 2022 | 21 | 0.370 |
Why?
|
| Genome, Human | 2 | 2021 | 62 | 0.360 |
Why?
|
| Public Policy | 2 | 2006 | 71 | 0.300 |
Why?
|
| Monkey Diseases | 2 | 2004 | 13 | 0.280 |
Why?
|
| United States | 12 | 2022 | 7367 | 0.270 |
Why?
|
| Social Conditions | 1 | 2006 | 4 | 0.270 |
Why?
|
| Social Problems | 1 | 2006 | 13 | 0.270 |
Why?
|
| Nanomedicine | 1 | 2006 | 19 | 0.260 |
Why?
|
| Health Care Sector | 1 | 2006 | 26 | 0.260 |
Why?
|
| Obesity | 1 | 2013 | 1076 | 0.260 |
Why?
|
| Azoospermia | 1 | 2005 | 1 | 0.250 |
Why?
|
| Nanotechnology | 1 | 2006 | 109 | 0.250 |
Why?
|
| Chromosome Aberrations | 3 | 2022 | 86 | 0.240 |
Why?
|
| Prenatal Care | 2 | 2011 | 117 | 0.230 |
Why?
|
| Preconception Care | 1 | 2003 | 14 | 0.220 |
Why?
|
| Alkaline Phosphatase | 2 | 1995 | 71 | 0.220 |
Why?
|
| Placenta | 2 | 1995 | 101 | 0.210 |
Why?
|
| Karyotyping | 3 | 2004 | 74 | 0.210 |
Why?
|
| Humans | 35 | 2022 | 68618 | 0.210 |
Why?
|
| Embryo Research | 1 | 2002 | 1 | 0.200 |
Why?
|
| Dietary Supplements | 2 | 2011 | 332 | 0.200 |
Why?
|
| alpha-Fetoproteins | 2 | 2019 | 22 | 0.200 |
Why?
|
| Policy | 1 | 2021 | 58 | 0.200 |
Why?
|
| Trisomy | 4 | 2022 | 47 | 0.190 |
Why?
|
| Ovarian Neoplasms | 1 | 2003 | 267 | 0.190 |
Why?
|
| Universities | 1 | 2021 | 191 | 0.180 |
Why?
|
| Stem Cells | 1 | 2002 | 248 | 0.180 |
Why?
|
| Chromosome Banding | 2 | 2004 | 24 | 0.170 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2019 | 47 | 0.170 |
Why?
|
| Chorionic Villi | 1 | 1998 | 5 | 0.160 |
Why?
|
| Pregnancy, Ectopic | 1 | 1998 | 16 | 0.160 |
Why?
|
| Female | 22 | 2022 | 38074 | 0.160 |
Why?
|
| Lomustine | 2 | 1988 | 10 | 0.150 |
Why?
|
| Sister Chromatid Exchange | 2 | 1988 | 7 | 0.150 |
Why?
|
| Vitamins | 2 | 2013 | 134 | 0.150 |
Why?
|
| DNA | 2 | 2020 | 597 | 0.140 |
Why?
|
| Guideline Adherence | 1 | 2019 | 287 | 0.140 |
Why?
|
| Odds Ratio | 2 | 2013 | 880 | 0.140 |
Why?
|
| Fetus | 2 | 2016 | 157 | 0.140 |
Why?
|
| Logistic Models | 3 | 2013 | 1420 | 0.130 |
Why?
|
| Case-Control Studies | 3 | 2013 | 1553 | 0.130 |
Why?
|
| Obstetric Labor, Premature | 1 | 1995 | 76 | 0.120 |
Why?
|
| Pregnancy Trimester, Second | 3 | 2021 | 58 | 0.120 |
Why?
|
| South Carolina | 4 | 2013 | 2752 | 0.120 |
Why?
|
| Isoenzymes | 1 | 1995 | 308 | 0.120 |
Why?
|
| Risk Factors | 5 | 2013 | 5731 | 0.110 |
Why?
|
| Adult | 13 | 2016 | 21403 | 0.110 |
Why?
|
| Infant, Newborn | 4 | 2013 | 2455 | 0.110 |
Why?
|
| Live Birth | 1 | 2013 | 8 | 0.110 |
Why?
|
| Stillbirth | 1 | 2013 | 12 | 0.110 |
Why?
|
| Educational Status | 1 | 2013 | 273 | 0.100 |
Why?
|
| Genetic Carrier Screening | 1 | 1991 | 25 | 0.100 |
Why?
|
| Genetic Counseling | 1 | 1992 | 45 | 0.100 |
Why?
|
| Adrenoleukodystrophy | 1 | 1991 | 45 | 0.100 |
Why?
|
| Family Health | 1 | 1991 | 83 | 0.100 |
Why?
|
| Attitude | 1 | 1992 | 121 | 0.100 |
Why?
|
| Infant, Low Birth Weight | 1 | 1991 | 84 | 0.090 |
Why?
|
| Trisomy 13 Syndrome | 2 | 2020 | 5 | 0.090 |
Why?
|
| Trisomy 18 Syndrome | 2 | 2020 | 6 | 0.090 |
Why?
|
| Laboratories | 2 | 2020 | 44 | 0.080 |
Why?
|
| Body Mass Index | 1 | 2013 | 867 | 0.080 |
Why?
|
| Health Personnel | 1 | 1992 | 286 | 0.080 |
Why?
|
| Attitude to Health | 1 | 1991 | 403 | 0.080 |
Why?
|
| Ascorbic Acid | 1 | 1988 | 45 | 0.080 |
Why?
|
| Surveys and Questionnaires | 2 | 2013 | 2800 | 0.070 |
Why?
|
| Infertility, Male | 2 | 2000 | 35 | 0.070 |
Why?
|
| Gestational Age | 2 | 2019 | 389 | 0.070 |
Why?
|
| Infant | 1 | 2013 | 2891 | 0.070 |
Why?
|
| Technology Assessment, Biomedical | 1 | 2006 | 24 | 0.070 |
Why?
|
| Consumer Product Safety | 1 | 2006 | 32 | 0.070 |
Why?
|
| Organizational Innovation | 1 | 2006 | 55 | 0.070 |
Why?
|
| Policy Making | 1 | 2006 | 51 | 0.070 |
Why?
|
| Leukemia-Lymphoma, Adult T-Cell | 1 | 2005 | 11 | 0.060 |
Why?
|
| Mosaicism | 1 | 2005 | 21 | 0.060 |
Why?
|
| Ultrasonography, Prenatal | 2 | 2011 | 79 | 0.060 |
Why?
|
| Eosinophilia | 1 | 2005 | 47 | 0.060 |
Why?
|
| Lymphoma | 1 | 2005 | 116 | 0.060 |
Why?
|
| Macaca nemestrina | 1 | 2004 | 23 | 0.060 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2005 | 116 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 13 | 1 | 2004 | 18 | 0.060 |
Why?
|
| Graft Rejection | 2 | 1998 | 458 | 0.060 |
Why?
|
| Granulosa Cell Tumor | 1 | 2003 | 3 | 0.050 |
Why?
|
| Adenocarcinoma, Papillary | 1 | 2003 | 12 | 0.050 |
Why?
|
| Primates | 1 | 2003 | 14 | 0.050 |
Why?
|
| Cystadenoma | 1 | 2003 | 10 | 0.050 |
Why?
|
| Carcinoma, Endometrioid | 1 | 2003 | 14 | 0.050 |
Why?
|
| International Classification of Diseases | 1 | 2003 | 85 | 0.050 |
Why?
|
| Teratoma | 1 | 2003 | 22 | 0.050 |
Why?
|
| Abnormalities, Multiple | 1 | 2004 | 109 | 0.050 |
Why?
|
| Developmental Disabilities | 1 | 2004 | 119 | 0.050 |
Why?
|
| Male | 8 | 2013 | 37321 | 0.050 |
Why?
|
| Interviews as Topic | 1 | 2003 | 392 | 0.050 |
Why?
|
| Abortion, Induced | 1 | 2002 | 18 | 0.050 |
Why?
|
| C-Peptide | 1 | 2001 | 23 | 0.050 |
Why?
|
| Chromosome Disorders | 2 | 2019 | 31 | 0.050 |
Why?
|
| Embryo, Mammalian | 1 | 2002 | 176 | 0.050 |
Why?
|
| Pregnancy Trimester, First | 1 | 2021 | 43 | 0.050 |
Why?
|
| Animals | 4 | 2004 | 20881 | 0.050 |
Why?
|
| Chromosome Inversion | 1 | 2000 | 5 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 2 | 1 | 2000 | 14 | 0.050 |
Why?
|
| Abortion, Habitual | 1 | 2000 | 13 | 0.050 |
Why?
|
| Amniotic Fluid | 1 | 2019 | 30 | 0.040 |
Why?
|
| Histocompatibility | 2 | 1998 | 17 | 0.040 |
Why?
|
| Risk Assessment | 1 | 2006 | 2007 | 0.040 |
Why?
|
| Chorionic Gonadotropin, beta Subunit, Human | 1 | 1998 | 10 | 0.040 |
Why?
|
| Embryonic and Fetal Development | 1 | 1998 | 74 | 0.040 |
Why?
|
| Leukocyte Transfusion | 1 | 1998 | 1 | 0.040 |
Why?
|
| Patients | 1 | 2018 | 69 | 0.040 |
Why?
|
| Macaca | 1 | 1998 | 24 | 0.040 |
Why?
|
| Prospective Studies | 2 | 1998 | 3705 | 0.040 |
Why?
|
| Macaca mulatta | 1 | 1998 | 77 | 0.040 |
Why?
|
| Indoles | 1 | 1998 | 146 | 0.040 |
Why?
|
| Microscopy, Fluorescence | 1 | 1998 | 261 | 0.040 |
Why?
|
| Fluorescent Dyes | 1 | 1998 | 191 | 0.030 |
Why?
|
| Maternal Age | 1 | 2016 | 70 | 0.030 |
Why?
|
| GPI-Linked Proteins | 1 | 1995 | 27 | 0.030 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 1995 | 63 | 0.030 |
Why?
|
| Pessaries | 1 | 1995 | 4 | 0.030 |
Why?
|
| Premenstrual Syndrome | 1 | 1995 | 4 | 0.030 |
Why?
|
| Genetic Diseases, Inborn | 2 | 1992 | 24 | 0.030 |
Why?
|
| Public Health Surveillance | 1 | 2015 | 18 | 0.030 |
Why?
|
| Bone Marrow Transplantation | 1 | 1995 | 149 | 0.030 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2015 | 68 | 0.030 |
Why?
|
| Sex Chromosomes | 1 | 1994 | 4 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 16 | 1 | 1994 | 18 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 1994 | 28 | 0.030 |
Why?
|
| Mutation | 1 | 2019 | 1213 | 0.030 |
Why?
|
| Fertility | 1 | 1994 | 60 | 0.030 |
Why?
|
| Spermatozoa | 1 | 1994 | 75 | 0.030 |
Why?
|
| Progesterone | 1 | 1995 | 115 | 0.030 |
Why?
|
| Tissue Donors | 1 | 1995 | 195 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 1995 | 507 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 1988 | 1745 | 0.030 |
Why?
|
| Nervous System Diseases | 1 | 1995 | 142 | 0.030 |
Why?
|
| Sex Determination Analysis | 1 | 1992 | 3 | 0.030 |
Why?
|
| Men | 1 | 1992 | 3 | 0.030 |
Why?
|
| Freedom | 1 | 1992 | 9 | 0.030 |
Why?
|
| Paternalism | 1 | 1992 | 6 | 0.030 |
Why?
|
| Abortion, Eugenic | 1 | 1992 | 2 | 0.030 |
Why?
|
| Beneficence | 1 | 1992 | 9 | 0.030 |
Why?
|
| Fetal Tissue Transplantation | 1 | 1992 | 12 | 0.030 |
Why?
|
| Ethics, Professional | 1 | 1992 | 8 | 0.030 |
Why?
|
| Reproductive Techniques, Assisted | 1 | 1992 | 6 | 0.030 |
Why?
|
| Insurance | 1 | 1992 | 7 | 0.030 |
Why?
|
| Personal Autonomy | 1 | 1992 | 22 | 0.030 |
Why?
|
| Huntington Disease | 1 | 1992 | 15 | 0.030 |
Why?
|
| Prevalence | 2 | 2011 | 1619 | 0.030 |
Why?
|
| Altruism | 1 | 1992 | 24 | 0.030 |
Why?
|
| X Chromosome | 1 | 1991 | 28 | 0.030 |
Why?
|
| Breast Neoplasms | 1 | 2001 | 1536 | 0.030 |
Why?
|
| T-Lymphocytes | 1 | 1995 | 597 | 0.020 |
Why?
|
| Medicine | 1 | 1992 | 52 | 0.020 |
Why?
|
| Specialization | 1 | 1992 | 66 | 0.020 |
Why?
|
| Chorionic Villi Sampling | 1 | 1991 | 6 | 0.020 |
Why?
|
| Women | 1 | 1992 | 40 | 0.020 |
Why?
|
| Truth Disclosure | 1 | 1992 | 48 | 0.020 |
Why?
|
| Disclosure | 1 | 1992 | 45 | 0.020 |
Why?
|
| Amniocentesis | 1 | 1991 | 12 | 0.020 |
Why?
|
| Confidentiality | 1 | 1992 | 62 | 0.020 |
Why?
|
| Genetic Linkage | 1 | 1991 | 90 | 0.020 |
Why?
|
| Goals | 1 | 1992 | 65 | 0.020 |
Why?
|
| Professional Competence | 1 | 1992 | 100 | 0.020 |
Why?
|
| Immunophenotyping | 2 | 2005 | 110 | 0.020 |
Why?
|
| Vitamin B Complex | 1 | 2011 | 26 | 0.020 |
Why?
|
| Consensus | 1 | 1992 | 211 | 0.020 |
Why?
|
| Employment | 1 | 1992 | 154 | 0.020 |
Why?
|
| Data Collection | 1 | 1992 | 420 | 0.020 |
Why?
|
| Diabetes, Gestational | 1 | 2011 | 81 | 0.020 |
Why?
|
| Flow Cytometry | 2 | 2005 | 489 | 0.020 |
Why?
|
| Genetic Therapy | 1 | 1992 | 291 | 0.020 |
Why?
|
| Family | 1 | 1992 | 293 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2015 | 2077 | 0.020 |
Why?
|
| Mass Screening | 1 | 2015 | 843 | 0.020 |
Why?
|
| Program Evaluation | 1 | 2011 | 502 | 0.020 |
Why?
|
| Decision Making | 1 | 1992 | 410 | 0.020 |
Why?
|
| Physicians | 1 | 1992 | 324 | 0.020 |
Why?
|
| Mutagenicity Tests | 1 | 1988 | 5 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 1991 | 1465 | 0.020 |
Why?
|
| Drug Synergism | 1 | 1988 | 260 | 0.020 |
Why?
|
| Middle Aged | 4 | 2015 | 21147 | 0.020 |
Why?
|
| Pilot Projects | 1 | 1991 | 1342 | 0.020 |
Why?
|
| Adolescent | 2 | 2000 | 8912 | 0.020 |
Why?
|
| Lymphocytes | 1 | 1988 | 228 | 0.020 |
Why?
|
| In Vitro Techniques | 1 | 1988 | 765 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 1988 | 567 | 0.020 |
Why?
|
| Cell Cycle | 1 | 1988 | 312 | 0.020 |
Why?
|
| Cytogenetics | 1 | 2005 | 7 | 0.020 |
Why?
|
| Antigens, Surface | 1 | 2005 | 71 | 0.020 |
Why?
|
| Remission Induction | 1 | 2005 | 111 | 0.020 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2011 | 767 | 0.020 |
Why?
|
| Diabetes Mellitus | 1 | 2011 | 694 | 0.020 |
Why?
|
| Syndrome | 1 | 2005 | 255 | 0.020 |
Why?
|
| Bone Marrow | 1 | 2005 | 168 | 0.010 |
Why?
|
| Facies | 1 | 2004 | 2 | 0.010 |
Why?
|
| Reflex, Abnormal | 1 | 2004 | 6 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 18 | 1 | 2004 | 17 | 0.010 |
Why?
|
| Lymph Nodes | 1 | 2005 | 258 | 0.010 |
Why?
|
| Neurologic Examination | 1 | 2004 | 107 | 0.010 |
Why?
|
| Child | 2 | 2005 | 6405 | 0.010 |
Why?
|
| Species Specificity | 1 | 2004 | 303 | 0.010 |
Why?
|
| Models, Genetic | 1 | 2004 | 161 | 0.010 |
Why?
|
| Biopsy | 1 | 2005 | 540 | 0.010 |
Why?
|
| Animals, Newborn | 1 | 2004 | 396 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 1988 | 2673 | 0.010 |
Why?
|
| Genotype | 1 | 2004 | 786 | 0.010 |
Why?
|
| Phenotype | 1 | 2004 | 947 | 0.010 |
Why?
|
| Chromosome Breakage | 1 | 2000 | 6 | 0.010 |
Why?
|
| Causality | 1 | 2000 | 82 | 0.010 |
Why?
|
| Drug Utilization | 1 | 2000 | 119 | 0.010 |
Why?
|
| Pedigree | 1 | 2000 | 159 | 0.010 |
Why?
|
| Prognosis | 1 | 2005 | 2093 | 0.010 |
Why?
|
| Sex Distribution | 1 | 2000 | 274 | 0.010 |
Why?
|
| Pregnancy Outcome | 1 | 2000 | 157 | 0.010 |
Why?
|
| Population Surveillance | 1 | 2000 | 285 | 0.010 |
Why?
|
| Leukemia, Myeloid, Accelerated Phase | 1 | 1998 | 2 | 0.010 |
Why?
|
| Transplantation, Homologous | 1 | 1998 | 242 | 0.010 |
Why?
|
| CD57 Antigens | 1 | 1995 | 3 | 0.010 |
Why?
|
| Biomarkers | 1 | 2001 | 1593 | 0.010 |
Why?
|
| CD8 Antigens | 1 | 1995 | 25 | 0.010 |
Why?
|
| CD3 Complex | 1 | 1995 | 35 | 0.010 |
Why?
|
| HLA-DR Antigens | 1 | 1995 | 41 | 0.010 |
Why?
|
| Luteinizing Hormone | 1 | 1995 | 31 | 0.010 |
Why?
|
| Irritable Mood | 1 | 1995 | 15 | 0.010 |
Why?
|
| beta-Endorphin | 1 | 1995 | 15 | 0.010 |
Why?
|
| Prolactin | 1 | 1995 | 61 | 0.010 |
Why?
|
| Follicle Stimulating Hormone | 1 | 1995 | 29 | 0.010 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 1995 | 135 | 0.010 |
Why?
|
| Body Temperature | 1 | 1995 | 116 | 0.010 |
Why?
|
| DNA Probes | 1 | 1994 | 57 | 0.010 |
Why?
|
| Base Sequence | 1 | 1995 | 1015 | 0.010 |
Why?
|
| Estradiol | 1 | 1995 | 176 | 0.010 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 1994 | 144 | 0.010 |
Why?
|
| Affect | 1 | 1995 | 218 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 1995 | 1447 | 0.010 |
Why?
|
| Anxiety | 1 | 1995 | 422 | 0.010 |
Why?
|
| Fetal Death | 1 | 1991 | 49 | 0.010 |
Why?
|
| Evaluation Studies as Topic | 1 | 1991 | 219 | 0.010 |
Why?
|
| Double-Blind Method | 1 | 1995 | 1738 | 0.010 |
Why?
|
| Cohort Studies | 1 | 1995 | 2358 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 1991 | 7277 | 0.000 |
Why?
|